GlassScriptPhysician profile
Brad S Mattison
NPI 1699757740
$8,238.74
in general payments reported to CMS, 2019-2025
37 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,424 · 2020: $593 · 2021: $935 · 2022: $768 · 2023: $1,224 · 2024: $594 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471 · Travel and Lodging: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.32 |
| Travel and Lodging | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Southern Edge Orthopaedics, INC. | $1,621.00 | 2019 | |
| Stryker Corporation | $1,537.60 | 2019-2025 | Anchorage, Hoffmann, Graftjacket |
| Smith+Nephew, INC. | $1,050.87 | 2019-2025 | Stravix, Grafix Pl, Collagenase Santyl |
| Treace Medical Concepts, INC. | $538.73 | 2022-2025 | |
| Djo, LLC | $399.44 | 2019-2025 | Cmf |
| Next Science LLC | $311.81 | 2023 | Xperience, Blastx, Surgx |
| Integra Lifesciences Corporation | $305.89 | 2019-2022 | |
| Horizon Therapeutics Plc | $297.93 | 2019-2021 | |
| Abbott Laboratories | $270.69 | 2024-2025 | Diamondback Peripheral, Esprit |
| Orthofix Medical, INC. | $210.57 | 2019-2020 | |
| Amgen INC. | $157.85 | 2025 | Krystexxa |
| Melinta Therapeutics, LLC | $149.71 | 2019 | |
| Organogenesis INC. | $132.86 | 2019-2024 | Puraply, Cygnus Dual |
| Aroa Biosurgery Incorporated | $128.04 | 2024 | |
| Boston Scientific Corporation | $122.73 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $106.60 | 2025 | |
| Kerecis Limited | $99.55 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Pacira Pharmaceuticals Incorporated | $98.22 | 2022 | |
| Wright Medical Technology, INC. | $94.16 | 2019 | |
| Depuy Synthes Sales INC. | $90.48 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $80.41 | 2023-2024 | Nuzyra |
| Biotissue Holdings INC. | $76.90 | 2022-2024 | |
| Stability Biologics, LLC | $51.84 | 2025 | |
| Trice Medical, INC. | $41.69 | 2025 | |
| Nabriva Therapeutics, Plc | $34.17 | 2021-2022 | |
| Davol INC. | $27.66 | 2020 | |
| Medshape, INC. | $26.32 | 2022 | |
| Reprise Biomedical, INC. | $23.39 | 2024 | Miro3d |
| Kci USA, INC. | $23.02 | 2020 | |
| Acera Surgical, INC. | $22.93 | 2022 | |
| Medtronic, INC. | $21.92 | 2023 | Intellis Adaptivestim |
| Nevro Corp. | $17.01 | 2023 | Senza |
| Zyla Life Sciences, INC. | $14.81 | 2020 | |
| Dynasplint Systems INC. | $14.28 | 2023 | Dynasplint |
| Mimedx Group, INC. | $13.56 | 2024 | |
| Arthrosurface Incorporated | $12.37 | 2020 | |
| Bioventus LLC | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Mattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.